[Antitumor activity of dioxadet compared with cisplatin on ascitic ovarian tumor in rats].

Antitumor activity of dioxadet in comparison with cisplatin was studied on the model of ascitic ovarian tumor in 32 female Wistar rats. Ascitic ovarian tumor was transplanted intraperitoneally 0.5 ml per rat dissolved by saline in ratio 1 to 4.

[Effect of olipifate on the wound healing proces and relapse after resection of Pliss lymphosarcoma].

The investigation was concerned with the influence of preliminary injections of Olipiphat, irrigation of operative wound and combination of both procedures on healing and relapse processes, following resection of Pliss lymphosarcoma at different stages after transplantation into rats. The physical condition of the animals after tumor resection on days 12, 10 or 7 of tumor growth was better than in controls, as a result of irrigation of the operative wound with Olipiphat or in combination with preliminary injections of the drug: they came out from anesthesia quicker, tidied themselves up and moved about the cage. Irrigation of the wound with Olipiphat or in combination with preliminary injections followed by longer survival after surgery performed at all stages of tumor growth.

[An experimental study of the antitumor properties of olipifat].

Olipiphat is an original lignin-based mix developed by special technology. It showed antitumor action against carcinoma of Ehrlich, breast adenocarcinoma Ca 755, melanoma B 16, lung carcinoma of Lewis, lymphosarcoma of Pliss, Walker's carcinoma, sarcoma 45 (tumor growth inhibition by 83-92%, increase in survival by 42-54%) and spontaneous murine tumors (the total of 9 pathologies). The drug was administered by 3-5 injections at 2-3 day intervals.

[Effect of dioxadet on tumors transplanted to the brain].

A newly-developed antitumor drug Dioxadet is capable of passing the blood-brain barrier. The specific activity of rat brain tissue ranged 8-55% of that of blood at different periods after intraperitoneal injection of 14C-labelled Dioxadet. Dioxadet treatment of mice and rats bearing intracranially-transplanted L1210 leukemia and glioma 35 was followed by a 38-48 and 29% increase in survival, respectively.